Author:
Coombs Geoffrey W.,Daley Denise A.,Bell Jan M.,Mowlaboccus Shakeel,Iredell Jon R.,
Abstract
Antimicrobials are an integral component of healthcare delivery. When resistance to an antimicrobial emerges, it has a significant impact on an individual’s treatment and the community more broadly. In Australia, to monitor antimicrobial resistance in human health, the Australian Group on Antimicrobial Resistance (AGAR) performs three ongoing blood-based antimicrobial surveillance programs: the Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP); the Australian Enterococcal Surveillance Outcome Program (AESOP); and the Gram-negative Surveillance Outcome Program (GnSOP). All data are available on the AGAR website and are included in the Australian Government Department of Health and Aged Care’s Antimicrobial Use and Resistance in Australia Surveillance System.
Reference10 articles.
1. Australian Commission on Safety and Quality in Health Care (2022) ACSQHC, Sydney, NSW, Australia.
2. Department of Health and Aged Care and Department of Agriculture, Fisheries and Forestry (2020) . Date published 13 March 2020. Commonwealth of Australia.
3. European Centre for Disease Prevention and Control (2023) European Union, Stockholm, Sweden. (last updated 17 November 2023)
4. Australian Group on Antimicrobial Resistance (AGAR) Australian Surveillance Outcome Program (ASSOP) bloodstream infection annual report 2022.;Commun Dis Intell,2023
5. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) bloodstream infection annual report 2022.;Commun Dis Intell,2023
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献